Accessibility Skip to Global Navigation Skip to Local Navigation Skip to Content Skip to Search Skip to Site Map Menu

Dr Liam Fernyhough

Liam Fernyhough

Honorary Research Fellow

BM BS, BMedSci(Nott), FRACP, FRCPA

^ Top of page

Publications

Hock, B. D., Macpherson, S. A., Fernyhough, L. J., & McKenzie, J. L. (2014). Chronic lymphocytic leukemia cells become both activated and immunosuppressive following interaction with CD3 and CD28 stimulated PBMC. Leukemia Research, 38(10), 1217-1223. doi: 10.1016/j.leukres.2014.06.004

Fernyhough, L. J., Hock, B. D., Taylor, J., Pearson, J., & Ganly, P. (2013). Survival of myeloma patients following the introduction of thalidomide as a second-line therapy: A retrospective study at a single New Zealand centre. Internal Medicine Journal, 43(2), 130-137. doi: 10.1111/j.1445-5994.2012.02819.x

Fernyhough, L. J., Buchan, V. A., McArthur, L. T., & Hock, B. D. (2013). Relative recovery of haematopoietic stem cell products after cryogenic storage of up to 19 years. Bone Marrow Transplantation, 48(1), 32-35. doi: 10.1038/bmt.2012.97

Hock, B. D., Fernyhough, L. J., Gough, S. M., & McKenzie, J. L. (2013). Clinical significance of plasma levels of soluble CD40 in patients with chronic lymphocytic leukemia. Open Journal of Blood Diseases, 3(1), 1-5. doi: 10.4236/ojbd.2013.31001

Zhang, M., Moore, G. A., Fernyhough, L. J., Barclay, M. L., & Begg, E. J. (2012). Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry. Analytical & Bioanalytical Chemistry, 404(6-7), 2091-2096. doi: 10.1007/s00216-012-6284-0

Journal - Research Article

Hock, B. D., Macpherson, S. A., Fernyhough, L. J., & McKenzie, J. L. (2014). Chronic lymphocytic leukemia cells become both activated and immunosuppressive following interaction with CD3 and CD28 stimulated PBMC. Leukemia Research, 38(10), 1217-1223. doi: 10.1016/j.leukres.2014.06.004

Fernyhough, L. J., Hock, B. D., Taylor, J., Pearson, J., & Ganly, P. (2013). Survival of myeloma patients following the introduction of thalidomide as a second-line therapy: A retrospective study at a single New Zealand centre. Internal Medicine Journal, 43(2), 130-137. doi: 10.1111/j.1445-5994.2012.02819.x

Hock, B. D., Fernyhough, L. J., Gough, S. M., & McKenzie, J. L. (2013). Clinical significance of plasma levels of soluble CD40 in patients with chronic lymphocytic leukemia. Open Journal of Blood Diseases, 3(1), 1-5. doi: 10.4236/ojbd.2013.31001

Fernyhough, L. J., Buchan, V. A., McArthur, L. T., & Hock, B. D. (2013). Relative recovery of haematopoietic stem cell products after cryogenic storage of up to 19 years. Bone Marrow Transplantation, 48(1), 32-35. doi: 10.1038/bmt.2012.97

Zhang, M., Moore, G. A., Fernyhough, L. J., Barclay, M. L., & Begg, E. J. (2012). Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry. Analytical & Bioanalytical Chemistry, 404(6-7), 2091-2096. doi: 10.1007/s00216-012-6284-0

Geertsema, L., Lucas, S. J. E., Cotter, J. D., Hock, B., McKenzie, J., & Fernyhough, L. J. (2011). The cardiovascular risk factor, soluble CD40 ligand (CD154), but not soluble CD40, is lowered by ultra-endurance exercise in athletes. British Journal of Sports Medicine, 45(1), 42-45. doi: 10.1136/bjsm.2008.051896

Hock, B. D., McKenzie, J. L., McArthur, L., Tansley, S., Taylor, K. G., & Fernyhough, L. J. (2010). CD38 as a prognostic marker in chronic lymphocytic leukaemia at a single New Zealand centre: Patient survival in comparison to age and sex matched population data. Internal Medicine Journal, 40(12), 842-849. doi: 10.1111/j.1445-5994.2009.02135.x

Hock, B. D., Fernyhough, L. J., Gough, S. M., Steinkasserer, A., Cox, A. G., & McKenzie, J. L. (2009). Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia. Leukemia Research, 33(8), 1089-1095. doi: 10.1016/j.leukres.2009.01.001

Fernyhough, L. J., Romeril, K., Carter, J., & Ritchie, D. S. (2005). Marrow fibrosis and pure red cell aplasia complicating early stage chronic lymphocytic leukaemia. Pathology, 37(2), 186-187.

^ Top of page

Conference Contribution - Published proceedings: Abstract

Trengrove, A. M., Schouten, J. E., & Fernyhough, L. (2012). Comparing pegylated and conventional G-CSF in the mobilisation of PBSC in patients with myeloma. Biology of Blood & Marrow Transplantation, 18(Suppl. 2), (pp. S384-S385). doi: 10.1016/j.bbmt.2011.12.491

Taylor, J., Fernyhough, L., Hock, B., & Ganly, P. (2011). Multiple myeloma patients treated in Christchurch, New Zealand: A retrospective analysis. Proceedings of the Inaugural International Cancer Symposium. Retrieved from http://www.wnmeds.ac.nz/cancersymposium/programme.html

Quach, H., Fernyhough, L. J., Henderson, R., Corbett, G. M., Honemann, D., Peinert, S., … Prince, M. (2011). A comparison of the efficacy and safety of low-dose lenalidomide plus low-dose dexamethasone (RD) with full-dose lenalidomide + dexamethasone (RD) in patients (PTs) with relapsed/refractory multiple myeloma (RRMM). Proceedings of the 13th International Myeloma Workshop (IMW). Retrieved from http://www.myeloma-paris2011.com/content/view/21/12/

Quach, H., Fernyhough, L., Henderson, R., Corbett, G., Lynch, K., Ritchie, D., … Prince, H. M. (2010). Lower-dose lenalidomide and dexamethasone reduces toxicity without compromising efficacy in patients with relapsed/refractory myeloma, who are aged ≥60 years or have renal impairment: Planned interim results of a Prospective Multicentre Phase II Trial. Proceedings of the 52nd American Society of Hematology (ASH)® Annual Meeting and Exposition. Retrieved from http://ash.confex.com/ash/2010/webprogram/Paper32912.html

Fernyhough, L., Tsai, J., & Spearing, R. (2006). Evans Syndrome with durable response to Rituximab. Proceedings of the Haematology Society of Australia & New Zealand (HSANZ) Annual Scientific Meeting. Retrieved from http://www.hsanz.org.au/resources/abstracts.cfm

Merriman, E., Patton, N., Fernyhough, L., & Ganly, P. (2006). Two cases of granulocytic sarcoma. Proceedings of the Haematology Society of Australia & New Zealand (HSANZ) Annual Scientific Meeting. Retrieved from http://www.hsanz.org.au/resources/abstracts.cfm

^ Top of page

Conference Contribution - Poster Presentation (not in published proceedings)

Fernyhough, L., Ebbett, A., Sanders, J., Spearing, R., Gibbons, S., Ganly, P., … Patton, N. (2005, October). Tandem high dose melphalan (HDM) and HLA identical-sibling allogeneic non myeloablative stem cell transplant (NMAT SCT) for multiple myeloma: A single centre experience. Poster session presented at the HSANZ/ANZSBT/ASTH Annual Scientific Meeting, Sydney, Australia.

More publications...